Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Awarded miR-122-Related Patent Coverage in Australia

Premium

Regulus Therapeutics said this week that that Australian Patent Office has recently granted certain claims in a company-controlled patent family covering the use of microRNA-122 in treating hepatitis C.

The intellectual property stems from the so-called Sarnow patent estate, which is owned by Stanford University and exclusively licensed to Regulus in the US, Europe, and Australia.

Regulus is developing a miR-122-targeting drug for the treatment of HCV in collaboration with GlaxoSmithKline (GSN 2/25/2010).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more